BACKGROUND: The role of additional androgen deprivation therapy (ADT) in prostate cancer (PCa) patients treated with combined HDR brachytherapy (HDR-BT) and external beam radiotherapy (EBRT) is still unknown. PATIENTS AND METHODS: Consecutive PCa patients classified as D'Amico intermediate and high-risk who underwent HDR-BT and EBRT treatment ± ADT at our institution between January 1999 and February 2009 were assessed. Multivariable Cox regression models predicting biochemical recurrence (BCR) were performed. BCR-free survival was assessed with Kaplan-Meier analyses. RESULTS: Overall, 392 patients were assessable. Of these, 221 (56.4 %) underwent trimodality (HDR-BT and EBRT and ADT) and 171 (43.6 %) bimodality (HDR-BT and EBRT) treatment. Additional ADT administration reduced the risk of BCR (HR: 0.4, 95 % CI: 0.3-0.7, p < 0.001). D'Amico high-risk patients had superior BCR-free survival when additional ADT was administered (log-rank p < 0.001). No significant difference for BCR-free survival was recorded when additional ADT was administered to D'Amico intermediate-risk patients (log-rank p = 0.2). CONCLUSIONS: Additional ADT administration improves biochemical control in D'Amico high-risk patients when HDR-BT and EBRT are combined. Physicians should consider the oncological benefit of ADT administration for these patients during the decision-making process.
BACKGROUND: The role of additional androgen deprivation therapy (ADT) in prostate cancer (PCa) patients treated with combined HDR brachytherapy (HDR-BT) and external beam radiotherapy (EBRT) is still unknown. PATIENTS AND METHODS: Consecutive PCa patients classified as D'Amico intermediate and high-risk who underwent HDR-BT and EBRT treatment ± ADT at our institution between January 1999 and February 2009 were assessed. Multivariable Cox regression models predicting biochemical recurrence (BCR) were performed. BCR-free survival was assessed with Kaplan-Meier analyses. RESULTS: Overall, 392 patients were assessable. Of these, 221 (56.4 %) underwent trimodality (HDR-BT and EBRT and ADT) and 171 (43.6 %) bimodality (HDR-BT and EBRT) treatment. Additional ADT administration reduced the risk of BCR (HR: 0.4, 95 % CI: 0.3-0.7, p < 0.001). D'Amico high-risk patients had superior BCR-free survival when additional ADT was administered (log-rank p < 0.001). No significant difference for BCR-free survival was recorded when additional ADT was administered to D'Amico intermediate-risk patients (log-rank p = 0.2). CONCLUSIONS: Additional ADT administration improves biochemical control in D'Amico high-risk patients when HDR-BT and EBRT are combined. Physicians should consider the oncological benefit of ADT administration for these patients during the decision-making process.
Authors: Jinka R Sathya; Ian R Davis; Jim A Julian; Qing Guo; Dean Daya; Ian S Dayes; Himu R Lukka; Mark Levine Journal: J Clin Oncol Date: 2005-02-20 Impact factor: 44.544
Authors: James Mohler; Robert R Bahnson; Barry Boston; J Erik Busby; Anthony D'Amico; James A Eastham; Charles A Enke; Daniel George; Eric Mark Horwitz; Robert P Huben; Philip Kantoff; Mark Kawachi; Michael Kuettel; Paul H Lange; Gary Macvicar; Elizabeth R Plimack; Julio M Pow-Sang; Mack Roach; Eric Rohren; Bruce J Roth; Dennis C Shrieve; Matthew R Smith; Sandy Srinivas; Przemyslaw Twardowski; Patrick C Walsh Journal: J Natl Compr Canc Netw Date: 2010-02 Impact factor: 11.908
Authors: Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart Journal: Lancet Date: 2002-07-13 Impact factor: 79.321
Authors: Razvan M Galalae; Alvaro Martinez; Tim Mate; Christina Mitchell; Gregory Edmundson; Nils Nuernberg; Stephen Eulau; Gary Gustafson; Michael Gribble; Gyoergy Kovács Journal: Int J Radiat Oncol Biol Phys Date: 2004-03-15 Impact factor: 7.038
Authors: E-M Thurner; S Krenn-Pilko; U Langsenlehner; W Renner; A Gerger; K S Kapp; T Langsenlehner Journal: Strahlenther Onkol Date: 2014-01-16 Impact factor: 3.621
Authors: Jose López-Torrecilla; Anna Boladeras; María Angeles Cabeza; Almudena Zapatero; Josep Jove; Luis M Esteban; Ivan Henriquez; Manuel Casaña; Carmen González-San Segundo; Antonio Gómez-Caamaño; Jose Luis Mengual; Asunción Hervás; Julia Luisa Muñoz; Gerardo Sanz Journal: Strahlenther Onkol Date: 2015-07-09 Impact factor: 3.621
Authors: Daniel S Engeler; Christoph Schwab; Armin F Thöni; Werner Hochreiter; Ladislav Prikler; Stefan Suter; Patrick Stucki; Johann Schiefer; Ludwig Plasswilm; Hans-Peter Schmid; Paul Martin Putora Journal: Strahlenther Onkol Date: 2015-06-23 Impact factor: 3.621